AbVir Biotherapeutics is developing a first-in-class preventive antibody therapy to protect immunosuppressed transplant recipients from Epstein–Barr virus (EBV) and its most serious consequence, post-transplant lymphoproliferative disorder (PTLD). By neutralizing EBV before viremia occurs, AbVir’s approach reduces PTLD risk without requiring immunosuppression tapering, thereby lowering the risk of graft rejection and graft-versus-host disease (GvHD). Licensed from Fred Hutchinson Cancer Center, the antibodies are supported by strong preclinical data. Current clinical practice intervenes only after lymphoma develops, whereas AbVir’s strategy prevents EBV viremia upstream, avoiding the substantial healthcare costs associated with PTLD diagnosis and treatment, hospitalization, and graft failure management. AbVir is initially targeting a ~$2.4B annual high-risk transplant market, with significant upside through platform expansion into EBV-associated autoimmune diseases, including multiple sclerosis and systemic lupus erythematosus.

AbVir Biotherapeutics

Org chart

Teams

Offices

AbVir Biotherapeutics

Org chart

Teams

Offices

Related companies